Noninvasive diagnosis of colorectal adenoma: The emerging potential of blood-based biomarkers

Table 4 Diagnostic potential of metabolites for adenomas[66,70,100,101]

Ref.	Study type and population	Biomarkers	Grouped control	AUC	Sensitivity (%)	Specificity (%)
Huang et al[100]	Retrospective multi-center case-control study; 219 CRC; 164 CRA	6 plasma metabolites, 3 lipids and lipid-like molecules, 2 organic oxygen compounds, 1 phenylpropanoid	CRC/CRA	0.905	84.0	81.7
Huang et al[100]	Retrospective multi-center case-control study; 164 CRA; 219 NC	7 plasma metabolites, 5 lipids and lipid-like molecules, 1 organic nitrogen compound, 1 organic acid	CRA/NC	0.997	97.0	97.7
Sun et al[70]	Multi-center case-control study; 111 CRC; 143 CRA; 119 NC	17 plasma metabolites	CRC/CRA	0.928	89.0	88.7
			CRA/NC	0.968	87.0	97.2
Guo et al[101]	Observational study; 19 CRC; 26 CRA; 20 NC	5 serum metabolites and 5 gut bacteria, 7 serum metabolites and 6 gut bacteria	CRC/CRA	0.850	84.21	76.92
			CRA/NC	0.880	75.00	96.15
Zhang et al[66]	Clinical case-control study; 200 CRC; 160 CRA	3 plasma metabolites ribitol, beta-hydroxybutyric acid, lactic acid	CRC/CRA	0.960

AUC: Area under the curve; CRC: Colorectal cancer; CRA: Colorectal adenoma; NC: Normal controls.